NRx Pharmaceuticals to Present Breakthrough Depression Treatment Developments at Emerging Growth Conference

NRx Pharmaceuticals and its subsidiary HOPE Therapeutics Inc. announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. The presentation will highlight the upcoming launch of a low-dose D-Cycloserine product that has demonstrated enhanced effectiveness of Transcranial Magnetic Stimulation for treating depression, representing a potential breakthrough in mental health treatment protocols. The integration of low-dose D-Cycloserine with Transcranial Magnetic Stimulation could potentially revolutionize depression treatment by enhancing the effectiveness of existing therapeutic approaches.

The company's expanded clinical operations in Florida and ongoing collaborations with the U.S. Department of Veterans Affairs to treat veterans suffering from suicidal depression and PTSD will also be discussed. These developments come as NRx Pharmaceuticals continues to advance its NMDA platform therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is developing multiple promising treatments, including NRX-100, a preservative-free intravenous ketamine that has received Fast Track Designation for treating Suicidal Ideation in Depression, including Bipolar Depression.

Another key development is NRX-101, an oral D-cycloserine/lurasidone combination that has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression. The company has recently filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program specifically targeting suicidal depression treatment. These regulatory advancements underscore the urgent need for effective treatments in the mental health space, particularly for conditions with high mortality rates like suicidal depression.

The presentation at the Noble Capital Markets conference represents an important opportunity for the company to showcase its progress in developing novel treatments for some of the most challenging mental health conditions. For more information about the company's development pipeline, visit https://www.nrxpharma.com. The company's forward-looking statements involve risks and uncertainties as detailed in their SEC filings available through their corporate disclosures.